Phase 1 Stomach Cancer Trial, Recruiting NCT07227168 Sponsor: Sutro Biopharma, Inc. Condition: Stomach Cancer
Back to Stomach Cancer

Phase 1 Stomach Cancer Trial, Recruiting

NCT07227168
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with certain advanced or spreading solid tumour cancers, confirmed by laboratory testing of tissue or cells. The specific cancer types included are: head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal or gastric (stomach) cancer, colorectal cancer, pancreatic ductal adenocarcinoma, cervical cancer, endometrial cancer, and urothelial carcinoma (a cancer of the urinary tract).
  • People aged 18 years or older.
  • People with a general health and activity level that falls within a specific range — roughly meaning they are either fully active or have only minor limitations in physical activity (confirm with trial site for exact assessment).
  • People who have already received all suitable standard treatments available in their region for their cancer type. The number of prior treatments allowed may vary depending on which part of the trial a person would enter, and whether they have certain genetic changes in their cancer (confirm with trial site for details).
  • People who have a tumour tissue sample available for testing.
  • People whose cancer can be measured using standard imaging criteria (known as RECIST 1.1).
  • People whose organs (such as kidneys, liver, and bone marrow) are functioning adequately (confirm with trial site for specific thresholds).
  • People taking blood-thinning medications, provided the dose has been stable for a period of time (confirm with trial site for exact requirements).

Who may not be able to join:

  • People with eye disorders.
  • People who have cancer that has spread to the brain and has not yet been treated.
  • People with certain pre-existing serious health conditions, including significant eye disorders, active lung inflammation, significant heart or blood vessel disease, or other major ongoing medical conditions that are not well controlled.
  • People who have previously had a solid organ transplant (such as a kidney or liver transplant) or a bone marrow transplant.
  • People who are currently participating in another clinical trial that involves an active treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 650-801-6416

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Sutro Biopharma, Inc.
Registry
ClinicalTrials.gov
Start date
7 November 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Part 1A: Number of participants with Dose-limiting Toxicities (DLTs); Part 1A, 1B: Percentage of participants with Treatment-Emergent Adverse Events (TEAEs), with severity determined according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale; Part 1A, 1B, 1C: Percentage of participants with clinical laboratory abnormalities, with severity determined according to the CTCAE v5.0 grading scale; Part 1B: Objective Response Rate (ORR); Part 1B: Disease control rate (DCR); Part 1B: Duration of Response (DOR); Part 1B: Progression-Free Survival (PFS); Part 1B: 12-month...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov